News Column

Cook Pharmica, LLC and Selexis SA Establish Customized Biologic Drug Development and Manufacturing Services Platform

July 7, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Cook Pharmica, LLC, a leading biopharmaceutical contract development and manufacturing organization (CDMO), and Selexis SA, a serial innovation company focused on biologic drug discovery and mammalian cell line development, have built a platform program to offer biopharmaceutical clients an integrated development and manufacturing solution for biologic drugs (see also Cook Medical).

Preliminary data from the Cook/Selexis-sponsored proof-of-concept program has been published in the June issue of BioProcess International in an article titled, "Rapid Development and Scale-Up Through Strategic Partnership: Case Study of an Integrated Approach to Cell-Line and Process Development for Therapeutic Antibodies."

This program combined key strengths of both companies. From the generation of stable and high performance CHO cell lines at Selexis to rapid process development, scale-up, cell culture manufacturing and final packaged sterile drug product manufacturing at Cook Pharmica, the collaboration optimized development timelines, according to the case study.1 In a nine-month proof-of-concept program, Cook Pharmica and Selexis were able to develop, transfer and scale up a commercially available monoclonal antibody. Selexis generated a high performance SURE CHO-M™ cell line expressing a monoclonal antibody (biosimilar) that was transferred and used with Cook Pharmica's scalable development process at their cGMP biologics manufacturing facility in Bloomington, IN. In this pilot program, the process developed between Selexis and Cook achieved titers above 3.5 g/L in 20L bioreactors and the purified monoclonal antibody product demonstrated full similarity in size, charges and glycan structure as compared to the innovator drug.2 The program demonstrated the viability of using a commercially available model molecule to scale up from 2-L through a 20-L pilot scale process that is scalable to GMP operations for clinical production.3 "These preliminary data from the proof-of-concept confirmed our ability in this case study to create a reliable process for the transfer and scale-up of a high expressing, stable clonal cell line, via a technology platform approach, that yielded commercial-ready titers with minimal development under the conditions of the study," according to Cook Pharmica's vice president and chief scientific officer, Vic Vinci, Ph.D. "In addition to this proof-of-concept program, we are very experienced in working with Selexis cell lines and are excited to be collaborating more with the Selexis team in the near future."

"We are extremely pleased with the data and the platform realized timeline from the Selexis/Cook Pharmica proof-of-concept program. In this program, we demonstrated that you can quickly go from DNA to protein in an optimized and seamless process," said Igor Fisch, Ph.D., CEO, Selexis SA. "This is another excellent example that Selexis can transfer a stable and high expressing clonal cell line to a CDMO with predicable results."

Learn more by visiting www.cookpharmica.com or www.selexis.com to view and download the case study detailing this successful collaborative model for expediting early phase development. About Cook PharmicaCook Pharmica is a privately held contract development and manufacturing organization (CDMO) that provides biopharmaceutical companies with a unique one-source, one-location model for development, clinical and commercial cell culture manufacturing, formulation, parenteral product manufacturing and secondary packaging. Centrally located in Bloomington, Indiana, Cook Pharmica is a wholly owned subsidiary of the Cook Group, which includes the largest privately held medical device manufacturer in the world, Cook Medical. The company maintains a simple goal: to deliver quality product in a timely manner. To do this effectively, Cook Pharmica has invested heavily in its facility, people and processes. About Selexis SAHeadquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ - novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

Cook Pharmica's website: www.cookpharmica.com Selexis' website: www.selexis.com 1,2,3 K Dhanasekharan, et al. Rapid Development and Scale-Up Through Strategic Partnership: Case Study of an Integrated Approach to Cell Line and Process Development. BioProcess Intl. 12(6)s 2014: 38-41

Keywords for this news article include: Antibodies, Therapy, Immunology, Blood Proteins, Immunoglobulins, Drug Development, Biopharmaceuticals.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters